Zydus Life Sciences promoter group member acquires 32,577 shares via transmission
Prashant Babubhai Patel acquired 32,577 Zydus Life Sciences shares via transmission. The shares were transferred from the estate of Late Jasodaben Babubhai Patel. Transaction occurred off-market on August 19, 2026. Post-acquisition holding represents 0.00% of total equity. Disclosure filed under SEBI PIT Regulations on August 24, 2026.
*this image is generated using AI for illustrative purposes only.
Zydus Life Sciences disclosed the transmission of 32,577 equity shares to Prashant Babubhai Patel, a member of its promoter group. The acquisition occurred on August 19, 2026, following the death of Jasodaben Babubhai Patel, also a promoter group member. The company filed the requisite Form B under SEBI (Prohibition of Insider Trading) Regulations, 2015, with stock exchanges on August 24, 2026.
The transaction was executed off-market and did not involve any trading on recognized exchanges. Prashant Babubhai Patel held no shares in the company prior to this transmission. Post-acquisition, his holding stands at 32,577 equity shares, representing 0.00% of the company’s total paid-up capital. The intimation was received by the company on August 21, 2026.
Regulatory Disclosure Details
The filing confirms that the change in holding falls under Regulation 7(2) read with Regulation 6(2) of the PIT Regulations, which mandates continual disclosure for promoters and their relatives. No derivatives trading associated with this event was reported.
| Parameter | Detail |
|---|---|
| Acquirer | Prashant Babubhai Patel |
| Category | Promoter Group |
| Mode of Acquisition | Transmission (Off Market) |
| Shares Acquired | 32,577 |
| Date of Acquisition | August 19, 2026 |
| Post-Acquisition Holding | 32,577 shares (0.00%) |
| Intimation Date | August 21, 2026 |
What the Numbers Show
The transmission results in a negligible change to the overall promoter group stake structure, given the 0.00% impact on total shareholding. This indicates that the transfer is likely an internal realignment within the promoter family rather than a strategic shift in control or ownership concentration at the group level. The absence of any open market activity suggests the transaction was settled purely through legal succession processes without impacting secondary market liquidity or price discovery mechanisms.
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.45% | -2.77% | -3.44% | +21.57% | +11.97% | +101.75% |
Will the internal realignment of promoter shares signal any upcoming changes in Zydus Life Sciences' corporate governance or board composition?
How might this succession event influence investor confidence regarding the long-term stability of the promoter group's leadership?
Are there any pending legal or regulatory complexities associated with the estate settlement that could delay future strategic decisions by the promoter group?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
